98 related articles for article (PubMed ID: 32761510)
21. NEK2 promotes TP53 ubiquitination to enhance the proliferation and migration of TP53 wild-type glioblastoma cells.
Zhang Y; Yu H; He M; Liu W; Xiao S; Wang X; Huang P; Huang Q
Neoplasma; 2024 May; ():. PubMed ID: 38764296
[TBL] [Abstract][Full Text] [Related]
22. erbB in NSCLC as a molecular target: current evidences and future directions.
Del Re M; Cucchiara F; Petrini I; Fogli S; Passaro A; Crucitta S; Attili I; De Marinis F; Chella A; Danesi R
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32820012
[TBL] [Abstract][Full Text] [Related]
23. EGFR-Dependent Extracellular Matrix Protein Interactions Might Light a Candle in Cell Behavior of Non-Small Cell Lung Cancer.
Hassanein SS; Abdel-Mawgood AL; Ibrahim SA
Front Oncol; 2021; 11():766659. PubMed ID: 34976811
[TBL] [Abstract][Full Text] [Related]
24. Identification of a novel spirocyclic Nek2 inhibitor using high throughput virtual screening.
Bhuiyan AI; Choi AH; Ghoshal S; Adiele UA; Dana D; Choi JY; Fath KR; Talele TT; Pathak SK
Bioorg Med Chem Lett; 2023 May; 88():129288. PubMed ID: 37094724
[TBL] [Abstract][Full Text] [Related]
25. Regulation of EGFR nanocluster formation by ionic protein-lipid interaction.
Wang Y; Gao J; Guo X; Tong T; Shi X; Li L; Qi M; Wang Y; Cai M; Jiang J; Xu C; Ji H; Wang H
Cell Res; 2014 Aug; 24(8):959-76. PubMed ID: 25001389
[TBL] [Abstract][Full Text] [Related]
26. Nuclear export signal mutation of epidermal growth factor receptor enhances malignant phenotypes of cancer cells.
Nie L; Wang YN; Hsu JM; Hou J; Chu YY; Chan LC; Huo L; Wei Y; Deng R; Tang J; Hsu YH; Ko HW; Lim SO; Huang K; Chen MK; Chiu TJ; Cheng CC; Fang YF; Li CW; Goverdhan A; Wu HJ; Lee CC; Wang WL; Hsu J; Chiao P; Wang SC; Hung MC
Am J Cancer Res; 2023; 13(4):1209-1239. PubMed ID: 37168336
[TBL] [Abstract][Full Text] [Related]
27. CCNA2 and NEK2 regulate glioblastoma progression by targeting the cell cycle.
Zhou HY; Wang YC; Wang T; Wu W; Cao YY; Zhang BC; Wang MD; Mao P
Oncol Lett; 2024 May; 27(5):206. PubMed ID: 38516683
[TBL] [Abstract][Full Text] [Related]
28. PTK2 is a potential biomarker and therapeutic target for EGFR- or TLRs-induced lung cancer progression via the regulation of the cross-talk between EGFR- and TLRs-mediated signals.
Kim JY; Shin JH; Kim MJ; Choi B; Kang Y; Choi J; Kim SH; Kwan D; Kim DH; Chun E; Lee KY
Biomark Res; 2024 May; 12(1):52. PubMed ID: 38816856
[TBL] [Abstract][Full Text] [Related]
29. Epigenomic study identifies a novel mesenchyme homeobox2-GLI1 transcription axis involved in cancer drug resistance, overall survival and therapy prognosis in lung cancer patients.
Armas-López L; Piña-Sánchez P; Arrieta O; de Alba EG; Ortiz-Quintero B; Santillán-Doherty P; Christiani DC; Zúñiga J; Ávila-Moreno F
Oncotarget; 2017 Sep; 8(40):67056-67081. PubMed ID: 28978016
[TBL] [Abstract][Full Text] [Related]
30. Shining a light on metabolic vulnerabilities in non-small cell lung cancer.
Dowling CM; Zhang H; Chonghaile TN; Wong KK
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188462. PubMed ID: 33130228
[TBL] [Abstract][Full Text] [Related]
31. High expression of NEK2 promotes gastric cancer progression via activating AKT signaling.
Wan H; Xu L; Zhang H; Wu F; Zeng W; Li T
J Physiol Biochem; 2021 Feb; 77(1):25-34. PubMed ID: 33201407
[TBL] [Abstract][Full Text] [Related]
32. miR‑139‑5p enhances cisplatin sensitivity in non‑small cell lung cancer cells by inhibiting cell proliferation and promoting apoptosis via the targeting of Homeobox protein Hox‑B2.
Du H; Bao Y; Liu C; Zhong A; Niu Y; Tang X
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33300085
[TBL] [Abstract][Full Text] [Related]
33. Kin17 facilitates thyroid cancer cell proliferation, migration, and invasion by activating p38 MAPK signaling pathway.
Jiang QG; Xiong CF; Lv YX
Mol Cell Biochem; 2021 Feb; 476(2):727-739. PubMed ID: 33201383
[TBL] [Abstract][Full Text] [Related]
34. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1.
Zhang X; Huang X; Xu J; Li E; Lao M; Tang T; Zhang G; Guo C; Zhang X; Chen W; Yadav DK; Bai X; Liang T
Nat Commun; 2021 Jul; 12(1):4536. PubMed ID: 34315872
[TBL] [Abstract][Full Text] [Related]
35. NEK2 plays an active role in Tumorigenesis and Tumor Microenvironment in Non-Small Cell Lung Cancer.
Bai R; Yuan C; Sun W; Zhang J; Luo Y; Gao Y; Li Y; Gong Y; Xie C
Int J Biol Sci; 2021; 17(8):1995-2008. PubMed ID: 34131401
[TBL] [Abstract][Full Text] [Related]
36. The Nek2 centrosome-mitotic kinase contributes to the mesenchymal state, cell invasion, and migration of triple-negative breast cancer cells.
Rivera-Rivera Y; Marina M; Jusino S; Lee M; Velázquez JV; Chardón-Colón C; Vargas G; Padmanabhan J; Chellappan SP; Saavedra HI
Sci Rep; 2021 Apr; 11(1):9016. PubMed ID: 33907253
[TBL] [Abstract][Full Text] [Related]
37. NEK2 promotes esophageal squamous cell carcinoma cell proliferation, migration and invasion through the Wnt/β-catenin signaling pathway.
Guo D; Yao W; Du X; Dong J; Zhang X; Shen W; Zhu S
Discov Oncol; 2023 May; 14(1):80. PubMed ID: 37233832
[TBL] [Abstract][Full Text] [Related]
38. Development and validation of a gene-based classification model for pN2 lung adenocarcinoma.
Zhu J; Wang W; Ma Y; Zhao J; Xiong Y
Transl Lung Cancer Res; 2023 Mar; 12(3):494-509. PubMed ID: 37057107
[TBL] [Abstract][Full Text] [Related]
39. Evaluating the Expression and Prognostic Value of Genes Encoding Microtubule-Associated Proteins in Lung Cancer.
Singharajkomron N; Yodsurang V; Seephan S; Kungsukool S; Petchjorm S; Maneeganjanasing N; Promboon W; Dangwilailuck W; Pongrakhananon V
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499051
[TBL] [Abstract][Full Text] [Related]
40. NEK2 promotes the migration and proliferation of ESCC via stabilization of YAP1 by phosphorylation at Thr-143.
Su W; Hu H; Ding Q; Wang M; Zhu Y; Zhang Z; Geng Z; Lin S; Zhou P
Cell Commun Signal; 2022 Jun; 20(1):87. PubMed ID: 35705994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
